Treatment With Dinutuximab in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma
Conditions: Ganglioneuroblastoma, Nodular; High-Risk Neuroblastoma Interventions: Biological: Dinutuximab; Drug: Irinotecan; Drug: Isotretinoin; Biological: Sargramostim; Drug: Temozolomide Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 12, 2020 Category: Research Source Type: clinical trials